Trends in price, spending, and utilization of omalizumab among Medicare beneficiaries

Lillian W Dattilo; Vinay K Rathi; Rodney J Schlosser; Zachary M Soler; George A Scangas; Alan D Workman; Stacey T Gray

doi:10.1002/alr.23185

Trends in price, spending, and utilization of omalizumab among Medicare beneficiaries

Int Forum Allergy Rhinol. 2023 Nov;13(11):2105-2108. doi: 10.1002/alr.23185. Epub 2023 Jun 6.

Authors

Lillian W Dattilo^{1

2}, Vinay K Rathi^{1

2}, Rodney J Schlosser^{3

4}, Zachary M Soler³, George A Scangas^{1

2}, Alan D Workman^{1

2}, Stacey T Gray^{1

2}

Affiliations

¹ Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts, USA.
² Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye & Ear Infirmary, Boston, Massachusetts, USA.
³ Division of Rhinology and Sinus Surgery, Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
⁴ Department of Surgery, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA.

PMID: 37199046
DOI: 10.1002/alr.23185

Abstract

Between January 2005 and January 2023, the average selling price of omalizumab increased by nearly 60%. Between 2016 and 2021, Medicare Part B and D spending on omalizumab totaled over $3.7 billion. Between 2016 and 2021, Medicare Part B and D utilization of omalizumab increased by approximately 30%.

Keywords: Medicare; biologics; biosimilars; chronic rhinosinusitis; cost; nasal polyps; omalizumab; price; utilization.